FTSE dragged lower by weak banks | 26 May 2021
FTSE dragged lower by weak banks
Stay updated with breaking news from Avct L. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FTSE dragged lower by weak banks
6 April 2021 | 09:26am StockMarketWire.com - Cancer therapies and diagnostics group Avacta entered into a global distribution agreement with ABCAM to sell the company'sSARS-CoV-2 research Affimer reagents. Under the worldwide, non-exclusive distribution agreement, ABCAM would enable the global research community to access Avacta's SARS-CoV-2 spike protein Affimer research reagents through its on-line catalogue. At 9:26am: [LON:AVCT] Avacta Group PLC share price was 0p at 111.5p Story provided by StockMarketWire.com Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account....
Avacta signs diagnostic licensing deal with Biokit
Avacta targets Covid-19 test kit launch by end of Q1; cancer drug trial to get underway by mid-2021
Avacta wins approval from UK health authorities for cancer drug trial